Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer

Prostate

Volumn 54, Issue 2, 2003, Pages 125-132

  Miyata, Yasuyoshi ^a   Sakai, Hideki ^a   Hayashi, Tomayoshi ^b   Kanetake, Hiroshi ^a  

^a NAGASAKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

IGF 1; IGFBP 3; Predictive value; Prostate cancer; PSA

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; CHLORMADINONE ACETATE; FLUTAMIDE; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; RELAPSE; TUMOR LOCALIZATION;

AGED; DISEASE-FREE SURVIVAL; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0037304341     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10175     Document Type: Article

References (25)

1. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocrinol Rev 1995;16:3-34.
2. Macaulay VM. Insulin-like growth factors and cancer. Br J Cancer 1992;65:311-320.
3. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R. Inhibition of growth of prostate cancer cell lines by peptide analogues of insulin-like growth factor I. Cancer Res 1993;53:1102-1106.
4. Iwamura M, Sluss PM, Casamento JB, Cockett ATK. Insulin like growth factor I: Action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-252.
5. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563-566.
6. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulose D. Insulin-like growth factor I and prostate cancer risk: A population-based, casecontrol study. J Natl Cancer Inst 1998;90:911-915.
7. Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factorbinding protein (IGFBP) superfamily. Endocrinol Rev 1999;20:761-787.
8. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000;92:1472-1489.
9. Kelley KM, Oh Y, Gargosky SE, Gucev Z, Matsumoto T, Hwa V, Ng L, Simpson DM, Rosenfeld RG. Insulin-like growth factorbinding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol 1996;28:619-637.
10. Kaicer E, Blat C, Imbenotte J, Troalen F, Cussenot O, Calvo F, Harel L. IGF binding protein-3 secreted by the prostate adenocarcinoma cells (PC-3): Differential effect on PC-3 and normal prostate cell growth. Growth Regul 1993;3:180-189.
11. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)binding protein-3 induces apoptosis and mediates the effect of transforming growth factor-betal on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 1997;272:12181-12188.
12. Rajah R, Khare A, Lee PDK, Cohen P. Insulin-like growth factorbinding protein-3 is partially responsible for high-seruminduced apoptosis in PC-3 prostate cancer cells. J Endocrinol 1999;163:487-494.
13. Kanety H, Madjar Y, Dagan Y, Levi J, Para MZ, Pariente C, Goldwasser B, Karasik A. Serum insulin-like growth factorbinding protein-2 (IGFBP-2) and IGFBP-3 is decreased in patients with prostate cancer: Correlation with serum prostatespecific antigen. J Clin Endocrinol Metab 1993;77:229-233.
14. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 1992;75:1046-1053.
15. Martin JL, Baxter RC. Insulin-like growth factor binding protein3: Biochemistry and physiology. Growth Regul 1992;2:88-99.
16. Tricoli JV, Winter DL, Hanlon AL, Raysor SL, Watkins-Bruner D, Pionover WH, Hanks GE. Radical differences in insulin-like growth factor binding protein-3 in men at increased risk of prostate cancer. Urology 1999;54:178-182.
17. UICC. International Union Against Cancer. TNM classification of malignant tumors. 5th ed. New York: Wiley-Liss; 1997.
18. Djavan B, Bursa B, Seitz C, Soeregi G, Remzi M, Basharkhah A, Wolfram R, Marberger M. Insulin-like growth factor-1 (IGF-1), IGF-1 density, and IGF/PSA ratio for prostate cancer detection. Urology 1999;54:603-606.
19. Wolk A, Anderson S, Mantzoros CS, Trichpoulos D, Adami H. Can measurement of IGF-1 and IGFBP-3 improve the sensitivity of prostate-cancer screening? Lancet 2000;356:1902-1903.
20. Finne P, Auvinen A, Koistinene H, Zhang W, Määttänen L, Rannikko S, Tammela T, Seppälä M, Hakama M, Stenman U. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 2000;85:2744-2747.
21. Khosravi J, Diamandi A, Mistry J, Scorilas A. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostate hyperplasia and prostate cancer. J Clin Endocrinol Metab 2001; 86:694-699.
22. Hampel OZ, Kattan MW, Yang G, Haidacher SJ, Saleh GY, Thompson TC, Wheeler TM, Marcelli M. Quantitative immunohistochemical analysis of insulin-like growth factor binding protein-3 in human prostatic adenocarcinoma: A prognostic study. J Urol 1998;159:2220-2225.
23. Colecchia M, Frigo B, Del Boca C, Guardamagna A, Zucchi A, Colloi D, Leopardi O. Detection of apoptosis by the TUNEL technique in clinically localised prostatic cancer before and after combined endocrine therapy. J Clin Pathol 1997;50:384-388.
24. Nickerson T, Pollak M. Bicalutamide (casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology 1999;54:1120-1125.
25. Zi X, Zhang J, Agarwal R, Pollak M. Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. Cancer Res 2000;60:5617-5620.